once they sign a distribution deal would expect a massive rerate, from lastest announcement expected in coming months:
Commercialisation and Product Distribution Plans:
GTG intends to introduce the new ‘GeneType for Colorectal Cancer’ and ‘GeneType for Breast Cancer’genetic tests to healthcare providers through a global network of distribution partners. The Company hasalready announced it is working with TGen in the United States and also Chinese partners connected to theHainan Free-Trade Zone. More announcements are anticipated in this regard in coming months as GTG movesto commercialise its suite of world-leading genetic tests.
GTG Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
